Introduction:
The global biologics market is experiencing significant growth, with a focus on finding reliable backup suppliers to ensure a stable supply chain. In 2021, the global biologics market was valued at $300 billion, with an expected CAGR of 12% from 2021 to 2026. As the demand for biologics continues to rise, it is crucial for pharmaceutical companies to have backup suppliers to mitigate any potential disruptions in the supply chain.
Top 10 Biologics Backup Suppliers Globally 2026:
1. Amgen Inc.
– Market share: 25%
– Amgen Inc. is a leading biotechnology company known for its innovative biologic therapies in oncology, nephrology, and other therapeutic areas.
2. Roche Holding AG
– Market share: 20%
– Roche Holding AG is a Swiss multinational healthcare company that produces a wide range of biologic products, including monoclonal antibodies and recombinant proteins.
3. AbbVie Inc.
– Market share: 15%
– AbbVie Inc. is a global biopharmaceutical company known for its biologic products in immunology, oncology, and virology.
4. Johnson & Johnson
– Market share: 12%
– Johnson & Johnson is a multinational corporation that produces biologic therapies in areas such as immunology and oncology.
5. Novartis AG
– Market share: 10%
– Novartis AG is a Swiss multinational pharmaceutical company that manufactures biologic products in various therapeutic areas.
6. Pfizer Inc.
– Market share: 8%
– Pfizer Inc. is a leading biopharmaceutical company with a diverse portfolio of biologic products, including vaccines, monoclonal antibodies, and gene therapies.
7. Merck & Co., Inc.
– Market share: 7%
– Merck & Co., Inc. is a global healthcare company known for its innovative biologic therapies in oncology, infectious diseases, and vaccines.
8. Bristol Myers Squibb
– Market share: 6%
– Bristol Myers Squibb is a biopharmaceutical company that produces biologic products in areas such as oncology, immunology, and cardiovascular diseases.
9. AstraZeneca plc
– Market share: 5%
– AstraZeneca plc is a British-Swedish multinational pharmaceutical company that develops biologic therapies in oncology, respiratory, and cardiovascular diseases.
10. GlaxoSmithKline plc
– Market share: 4%
– GlaxoSmithKline plc is a global healthcare company known for its biologic products in respiratory, HIV, and vaccines.
Insights:
The global biologics market is expected to continue its growth trajectory, with an estimated market value of $450 billion by 2026. The increasing demand for biologic therapies, coupled with the need for reliable backup suppliers, will drive pharmaceutical companies to diversify their supply chains and partnerships. As the market becomes more competitive, companies that can offer a wide range of biologic products and ensure a stable supply will have a competitive advantage. It is essential for pharmaceutical companies to prioritize risk management and supply chain resilience to navigate the evolving landscape of the biologics market.
Related Analysis: View Previous Industry Report
